Mass Response of Tumor Cells As a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting
- Conditions
- Carcinoma, RenalCarcinomaCarcinoma of Unknown PrimaryCarcinoma of the LarynxCarcinoma of EsophagusCarcinoma of the CervixCarcinoma of the VulvaPancreatic CancerAscites, MalignantCarcinoma, Non-Small-Cell Lung
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Travera Inc
- Target Recruit Count
- 200
- Registration Number
- NCT05461430
- Locations
- 🇺🇸
xCures, Oakland, California, United States
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Withdrawn
- Conditions
- Carcinoma, Non-Small-Cell LungCarcinoma BladderCarcinoma of the Oral CavityStage III Breast CancerCarcinoma, Renal CellCarcinoma, Small Cell LungCarcinoma of the Head and NeckCarcinoma of the AnusCarcinoma of the LarynxCarcinoma of the Vulva
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Travera Inc
- Target Recruit Count
- 630
- Registration Number
- NCT04985357
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
Terminated
- Conditions
- Multiple Myeloma in Relapse
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Travera Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03777410
- Locations
- 🇺🇸
Weill Cornell Medicine - New York Presbyterian, New York, New York, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath